Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochlorid - roztroušená skleróza, relaps-remitentní - imunosupresiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1)orpatients s rychle se vyvíjející těžkou relabující-remitentní formou roztroušené sklerózy definovanou 2 nebo více relapsy v jednom roce a s 1 nebo více gadolinium enhancing lézí na mri mozku nebo významné zvýšení zátěže t2 lézí ve srovnání s předchozí nedávnou mri.

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - abirateron acetátu - prostatetické novotvary - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuskulární blokáda - všechny ostatní terapeutické přípravky - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochlorid - roztroušená skleróza, relaps-remitentní - imunosupresiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 2220 fentanyl - transdermální náplast - 100mcg/h - fentanyl

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 2220 fentanyl - transdermální náplast - 12mcg/h - fentanyl

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 2220 fentanyl - transdermální náplast - 25mcg/h - fentanyl

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 2220 fentanyl - transdermální náplast - 50mcg/h - fentanyl

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 2220 fentanyl - transdermální náplast - 75mcg/h - fentanyl

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

mylan ireland limited, dublin array - 15542 monohydrÁt pramipexol-dihydrochloridu - tableta s prodlouženým uvolňováním - 0,26mg - pramipexol